Novo Nordisk has submitted a marketing authorization application to the European Medicines Agency for the approval of faster-acting insulin aspart. Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with Type 1 and Type 2 diabetes. Faster-acting insulin aspart is insulin aspart (NovoRapid) in a new formulation in which two new excipients have been added to ensure early and fast absorption.

Novo Nordisk expects to file the new drug application for faster-acting insulin aspart to the US Food and Drug Administration before year-end 2015.

Novo Nordisk intends to make faster-acting insulin aspart available in the prefilled delivery device FlexTouch.

Source: Novo Nordisk